ArticleFrontiers in oncology2023
Self-attention random forest for breast cancer image classification.
Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 29 citations in OpenAlex.
- Cross-modal attentive fusion network for tri-modal lesion growth prediction.Scientific reports · 2026Article
- Machine learning and artificial intelligence in liquid biopsy-based early detection of pancreatic cancer: a scoping review.BJC reports · 2026Review
- An integrated approach of feature selection and machine learning for early detection of breast cancer.Scientific reports · 2025Article
- Enhanced Multi-Class Breast Cancer Classification from Whole-Slide Histopathology Images Using a Proposed Deep Learning Model.Diagnostics (Basel, Switzerland) · 2025Article
- WeNet-RF: An Automatic Classification Model for Financial Reimbursement Budget Items.PloS one · 2025Article
- The Application of Artificial Intelligence to Cancer Research: A Comprehensive Guide.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Early screening and diagnosis of breast cancer can not only detect hidden diseases in time, but also effectively improve the survival rate of patients. Therefore, the accurate classification of breast cancer images becomes the key to auxiliary diagnosis. Methods: In this paper, on the basis of extracting multi-scale fusion features of breast cancer images using pyramid gray level co-occurrence matrix, we present a Self-Attention Random Forest (SARF) model as a classifier to explain the importance of fusion features, and can perform adaptive refinement processing on features, thus, the classification accuracy can be improved. In addition, we use GridSearchCV technique to optimize the hyperparameters of the model, which greatly avoids the limitation of artificially selected parameters. Results: To demonstrate the effectiveness of our method, we perform validation on the breast cancer histopathological image-BreaKHis. The proposed method achieves an average accuracy of 92.96% and a micro average AUC value of 0.9588 for eight-class classification, and an average accuracy of 97.16% and an AUC value of 0.9713 for binary classification on BreaKHis dataset. Discussion: For the sake of verify the universality of the proposed model, we also conduct experiments on MIAS dataset. An excellent average classification accuracy is 98.79% on MIAS dataset. Compared to other state-of-the-art methods, the experimental results demonstrate that the performance of the proposed method is superior to that of others. Furthermore, we can analyze the influence of different types of features on the proposed model, and provide theoretical basis for further optimization of the model in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.